What is HC Wainwright’s Forecast for VKTX FY2025 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for shares of Viking Therapeutics in a report released on Thursday, October 23rd. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($2.73) per share for the year, down from their previous estimate of ($2.48). HC Wainwright has a “Buy” rating and a $102.00 price objective on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.94) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.14). During the same period in the prior year, the business posted ($0.22) earnings per share. The business’s revenue was up .0% compared to the same quarter last year.

Several other research firms have also recently issued reports on VKTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Citigroup boosted their target price on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. JPMorgan Chase & Co. dropped their target price on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday. B. Riley upgraded Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. Finally, Zacks Research cut Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 21st. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $85.62.

Viking Therapeutics Trading Up 4.4%

NASDAQ VKTX opened at $35.93 on Monday. The business’s 50 day moving average is $28.44 and its two-hundred day moving average is $28.92. Viking Therapeutics has a 12-month low of $18.92 and a 12-month high of $81.73. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -16.95 and a beta of 0.64.

Institutional Investors Weigh In On Viking Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP grew its holdings in shares of Viking Therapeutics by 58.4% in the 2nd quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 352 shares during the period. Glass Jacobson Investment Advisors llc purchased a new stake in Viking Therapeutics in the 2nd quarter valued at approximately $28,000. Quarry LP lifted its stake in Viking Therapeutics by 1,621.4% in the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,135 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Viking Therapeutics in the 2nd quarter valued at approximately $29,000. Finally, Avion Wealth lifted its stake in Viking Therapeutics by 1,157.0% in the 3rd quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.